Table 1.

Studies demonstrating the efficacy and safety of loteprednol etabonate (LE) 0.5 % for postoperative inflammation

Study parameters	Stewart et al. [13]	LE postoperative study group 2 1998 [2]	Grigorian et al. [31]	Stewart [30]
Comparator	Vehicle	Vehicle	1 % (PA)	Fluorometholone acetate 0.1 % (FA)
No. of patients	203	227	20	30
Treatment duration (weeks)	2	2	4	2
Patients with resolution of ACIa at final visit (%)	LE group—64	LE group—55	LE group—60	LE group—60
	Vehicle—29	Vehicle—28	PA group—50	FA group—100
Mean IOP at final visit	Mean decrease in IOP of 1–2 mmHg for both treatment groups	Mean decrease in IOP of 1–2 mmHg for both treatment groups	LE group—12 ± 3 mmHg	Not reported
			PA group—16 ± 1 mmHg
Clinically significant increases in IOP (≥10 mmHg)	n = 3 for loteprednol etabonate; n = 0 for vehicle	n = 0 for loteprednol etabonate; n = 1 for vehicle	Not reported	Not reported

ACI anterior chamber inflammation, IOP intraocular pressure, LE loteprednol etabonate, PA prednisolone acetate, FA fluorometholone acetate

^aResolution of ACI defined as anterior chamber cell count <5 and flare Grade 0 (none)